{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:04:30Z","timestamp":1773234270348,"version":"3.50.1"},"reference-count":14,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S proteasome. Ocular side effects of bortezomib are rare. In this report, we present 2 patients with active MM in whom persistent chalazia became a therapy-interfering complication of treatment with bortezomib. Both patients had relapsed ISS III B kappa light chain myeloma, and they were responding to treatment with bortezomib until chalazia\u2212which caused intolerable discomfort\u2212started. In both patients discontinuation of bortezomib was necessary for chalazia to heal, and restarting of bortezomib was associated with relapse of chalazia.<\/jats:p>","DOI":"10.4081\/hr.2015.5729","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T10:51:13Z","timestamp":1434365473000},"page":"5729","source":"Crossref","is-referenced-by-count":12,"title":["Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy"],"prefix":"10.3390","volume":"7","author":[{"given":"Charles","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Mukhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Shinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olcay","family":"Batuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/17474086.2014.870030","article-title":"An overview of the progress in the treatment of multiple myeloma","volume":"7","author":"Kyle","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"ref2","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma Cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"232037","DOI":"10.1155\/2011\/232037","article-title":"Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101","volume":"2011","author":"Braunstein","year":"2011","journal-title":"J Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobirial","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref6","article-title":"Clinical ophthalmology: a systematic approach","author":"Kanski","year":"1994"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004397-196403000-00002","article-title":"Inflammations of the lid","volume":"4","author":"Ballen","year":"1964","journal-title":"Int Ophthalmol Clin"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/dc.20092","article-title":"Cytopathology of chalazia","volume":"31","author":"Dhaliwal","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"ref9","first-page":"311","article-title":"Management of chalazia in general practice","volume":"38","author":"Gilchrist","year":"2009","journal-title":"Aust Fam Physician"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2014.04.021","article-title":"Chalazia associated with bortezomib therapy for multiple myeloma","volume":"121","author":"Grob","year":"2014","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.pcan.4500939","article-title":"Docetaxel-induced meibomian duct inflammation and blockage leading to chalazion formation","volume":"10","author":"Gupta","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/IOP.0b013e318201d32f","article-title":"Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease","volume":"27","author":"Cunniffe","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.eye.6701816","article-title":"Virus-induced chalazion","volume":"20","author":"Mansour","year":"2006","journal-title":"Eye (Lond.)"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2013.772294","article-title":"Herpes zoster complicating bortezomib therapy of relapsed\/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials","volume":"54","author":"Solh","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/5729\/4669","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/5729\/4903","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/7\/2\/5729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:00:57Z","timestamp":1645599657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/7\/2\/5729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,6]]}},"alternative-id":["hr.2015.5729"],"URL":"https:\/\/doi.org\/10.4081\/hr.2015.5729","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,9]]}}}